Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $6.38 USD
Change Today -0.09 / -1.39%
Volume 1.2K
EKTAF On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
Frankfurt
As of 8:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

elekta ab-b shs (EKTAF) Snapshot

Open
$6.10
Previous Close
$6.47
Day High
$6.38
Day Low
$6.10
52 Week High
09/9/14 - $11.00
52 Week Low
07/7/15 - $6.04
Market Cap
2.4B
Average Volume 10 Days
1.2K
EPS TTM
--
Shares Outstanding
368.6M
EX-Date
09/2/15
P/E TM
--
Dividend
$0.50
Dividend Yield
3.37%
Current Stock Chart for ELEKTA AB-B SHS (EKTAF)

Related News

No related news articles were found.

elekta ab-b shs (EKTAF) Related Businessweek News

No Related Businessweek News Found

elekta ab-b shs (EKTAF) Details

Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Axesse, a stereotactic radiation therapy system; Elekta Compact, a gateway to RT for oncology centers; Elekta Synergy system that visualizes tumor targets and normal tissue, and their movement between and during fractions; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloading platforms; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; Esteya for treating skin cancer; and applicators. Further, the company provides software products, including MOSAIQ oncology information system; Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; and METRIQ, a cancer registry data solution. It also offers installation and implementation, service and support, remote, upgrades and accessories, and financial solutions, as well as training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

3,844 Employees
Last Reported Date: 08/11/15
Founded in 1972

elekta ab-b shs (EKTAF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

elekta ab-b shs (EKTAF) Key Developments

Elekta AB Reports Audited Consolidated and Parent Company Earnings Results for the Year Ended April 30, 2015

Elekta AB reported audited consolidated and parent company earnings results for the year ended April 30, 2015. For the year on consolidated basis, the company reported net sales of SEK 10,839 million against SEK 10,694 million a year ago. Operating results was SEK 937 million against SEK 1,727 million a year ago. Profit before tax was SEK 716 million against SEK 1,502 million a year ago. Profit for the year was SEK 558 million against SEK 1,152 million a year ago. Profit attributable to parent company shareholders was SEK 552 million against SEK 1,148 million a year ago. Earnings per share diluted were SEK 1.45 against SEK 3.00 per share a year ago. Cash flow from operating activities was SEK 1,823 million against SEK 1,275 million a year ago. Investments in intangible assets were SEK 685 million against SEK 492 million a year ago. Investments in machinery and equipment were SEK 297 million against SEK 234 million a year ago. For the year on parent basis, the company reported operating results of SEK 92 million against SEK 56 million a year ago. Profit before tax was SEK 667 million against SEK 593 million a year ago. Profit for the year was SEK 658 million against SEK 584 million a year ago. Cash flow from operating activities was SEK 790 million against SEK 366 million a year ago.

Elekta's Leksell Gamma Knife® Icon™ Radiosurgery System Receives 510(K) Clearance from the US Food and Drug Administration

Elekta's Leksell Gamma Knife® Icon™ radiosurgery system has received 510(k) clearance from the US Food and Drug Administration, enabling US health care providers to offer this advanced technology to their patients. With stereotactic imaging, online Adaptive DoseControl™, ultra-precise dose delivery and the availability of frameless treatments, Icon is capable of treating virtually any target in the brain, regardless of type, location or volume. Gamma Knife Icon represents the sixth generation of the company's Leksell Gamma Knife system, a technology that has been in use worldwide and continually evolving since the 1980s. Gamma Knife radiosurgery is a gentler alternative to traditional brain surgery for illnesses such as metastatic disease, which is cancer that has travelled to the brain from elsewhere in the body. With pinpoint accuracy, the system delivers up to thousands of low-intensity radiation beams to one or more targets in a single session.

Elekta AB Announces Executive Appointments

Elekta AB appointed Johan Malmqvist and Annika Espander Jansson as directors of the Board. Annika Espander Jansson has 25 years' experience as an analyst and investor, as well as from executive positions within the financial markets and the pharmaceutical industry. She is the founder of Asperia AB and has been the CEO since June 2013. Johan Malmqvist has extensive experience from the medical technology industry. Johan Malmqvist was born in 1961 and holds a BA from Stockholm School of Economics. From 1997 to 2015, he was president and CEO of Getinge AB.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKTAF:US $6.38 USD -0.09

EKTAF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Accuray Inc $6.89 USD +0.12
Eckert-Ziegler Bebig €1.06 EUR -0.008
Icad Inc $3.97 USD +0.07
MRI Interventions Inc $0.75 USD -0.034
RaySearch Laboratories AB kr112.00 SEK -5.25
View Industry Companies
 

Industry Analysis

EKTAF

Industry Average

Valuation EKTAF Industry Range
Price/Earnings 36.2x
Price/Sales 1.8x
Price/Book 3.0x
Price/Cash Flow 35.0x
TEV/Sales 0.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELEKTA AB-B SHS, please visit www.elekta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.